[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Carmen Fava\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100632842","energia-personalized-exercise-program-for-fatigue-in-patients-with-myeloproliferative-neoplasms-and-chronic-myeloid-leukemia-100632842",false,"NCT07518940","ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia","ENERGIA: Exercise in Rare Hematologic Diseases With Individualized and Adapted Management","ENERGIA","Inclusion Criteria:\n\nAge ≥18 years Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, low-risk primary myelofibrosis) or chronic myeloid leukemia according to WHO criteria Clinical and therapeutic stability for at least 8 weeks prior to enrollment Presence of clinically relevant fatigue as assessed by validated disease-specific questionnaires General clinical condition compatible with participation in a supervised exercise program of at least moderate intensity Absence of contraindications to cardiopulmonary exercise testing No participation in structured exercise or rehabilitation programs within the previous 3 months Minimum hematological safety parameters (hemoglobin \\>10 g\u002FdL; platelets \\>100,000 × 10⁹\u002FL) Ability to understand and comply with study procedures Provision of written informed consent\n\nExclusion Criteria:\n\nUnstable cardiovascular conditions (including uncontrolled heart failure, recent myocardial ischemia, symptomatic ventricular arrhythmias, or unexplained syncope) Thrombotic or hemorrhagic events within the previous 3 months Active acute or chronic infections Severe orthopedic or neurological conditions limiting the ability to perform exercise or functional testing Severe systemic diseases (e.g., advanced renal or hepatic failure, active secondary malignancy, uncontrolled psychiatric disorders) Any clinical condition that, in the investigator's judgment, may compromise safety or adherence to the protocol Indication for a primary structured rehabilitation program based on physiatric evaluation","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates whether a personalized, supervised exercise program can improve fatigue and physical function in patients with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Although many patients achieve good disease control with modern therapies, they often experience persistent symptoms such as fatigue that significantly affect daily life.\n\nParticipants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. The program consists of two supervised sessions per week, along with additional home-based aerobic activity. Before and after the program, participants will undergo comprehensive assessments, including cardiopulmonary exercise testing, physical function tests, questionnaires on fatigue and quality of life, and blood sample collection.\n\nThe study aims to determine whether this type of exercise program is feasible and safe, and whether it can reduce fatigue and improve physical capacity, quality of life, and biological markers related to inflammation and metabolism. Participants will also be followed after the intervention to evaluate whether the benefits are maintained over time.",[27,28,29,30,31],"Myeloproliferative Disease","Polycythemia Vera","Thrombocythemia Essential","Myelofibrosis, Primary","Chronic Myeloid Leukemia (CML)",[33,34,35,36,37,38,39,40,41,42,43,44],"Myeloproliferative Neoplasms;","Chronic Myeloid Leukemia","Exercise Intervention","Cancer-Related Fatigue","Fatigability","Physical Activity","Cardiorespiratory Fitness","Quality of Life","physical exercise","Immunometabolism","Metabolomics","Feasibility","NOT_YET_RECRUITING","2026-04-01",{"date":48,"type":49},"2026-04-09","ACTUAL",{"date":51,"type":21},"2026-08-01",{"date":53,"type":21},"2027-12-31",{"name":55,"class":56},"Carmen Fava","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":57},"100571767","interaction-between-gut-microbiota-and-tkis-in-defining-the-clinical-outcomes-of-patients-with-cml-100571767","NCT06724536","Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML","Interaction Between Gut Microbiota and Tyrosine Kinase Inhibitors in Defining the Clinical Outcomes of Patients With Chronic Myeloid Leukemia","MICROBIO-LMC","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Chronic Myeloid Leukemia Patients\n* Any stage of the disease\n\nExclusioni Criteria:\n\nnone",{"count":67,"type":21},100,"OBSERVATIONAL","Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity. In the case of Chronic Myeloid Leukemia (CML), treatment with Tyrosine Kinase Inhibitors (TKIs) restores immunosurveillance; in particular deep molecular response (DMR) is associated with increased levels of NK and CD8+ Tcells. There is no literature on the effects of GM on CML outcomes. This project aims to identify a microbial signature associated with a higher probability of achieving DMR.",[71],"Leukemia,Myeloid, Chronic",[73,74,75,76],"chronic myeloid leukemia","gut","microbiota","tyrosine kinase inhibitors","RECRUITING","2024-12-04",{"date":80,"type":49},"2024-12-09",{"date":82,"type":49},"2022-10-01",{"date":84,"type":21},"2026-10-01",{"name":55,"class":56},""]